

# Michal J Besser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6813456/publications.pdf>

Version: 2024-02-01

71  
papers

3,803  
citations

201658

27  
h-index

133244

59  
g-index

73  
all docs

73  
docs citations

73  
times ranked

5918  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2010, 16, 2646-2655.	7.0	412
2	Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. <i>Clinical Cancer Research</i> , 2013, 19, 4792-4800.	7.0	330
3	Early and late hematologic toxicity following CD19 CAR-T cells. <i>Bone Marrow Transplantation</i> , 2019, 54, 1643-1650.	2.4	254
4	Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence. <i>Cell</i> , 2019, 179, 236-250.e18.	28.9	206
5	Identification of bacteria-derived HLA-bound peptides in melanoma. <i>Nature</i> , 2021, 592, 138-143.	27.8	187
6	TIL therapy broadens the tumor-reactive CD8 <sup>+</sup> T cell compartment in melanoma patients. <i>Oncotarget</i> , 2012, 1, 409-418.	4.6	171
7	MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. <i>Journal of Clinical Investigation</i> , 2013, 123, 2703-2718.	8.2	149
8	Establishment and Large-scale Expansion of Minimally cultured "Young" Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy. <i>Journal of Immunotherapy</i> , 2011, 34, 212-220.	2.4	144
9	Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. <i>Oncotarget</i> , 2016, 7, 5110-5117.	1.8	135
10	Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 1347.	4.8	135
11	Minimally Cultured or Selected Autologous Tumor-infiltrating Lymphocytes After a Lympho-depleting Chemotherapy Regimen in Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2009, 32, 415-423.	2.4	113
12	The nuclear translocation of ERK1/2 as an anticancer target. <i>Nature Communications</i> , 2015, 6, 6685.	12.8	104
13	Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1485-1492.	4.1	93
14	Regulation of Cancer Aggressive Features in Melanoma Cells by MicroRNAs. <i>PLoS ONE</i> , 2011, 6, e18936.	2.5	77
15	Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.	1.6	60
16	Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1300-1310.	4.1	58
17	Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1221-1230.	4.2	55
18	Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma. <i>PLoS ONE</i> , 2013, 8, e57160.	2.5	53

#	ARTICLE	IF	CITATIONS
19	A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. <i>Oncotarget</i> , 2015, 6, 28999-29015.	1.8	53
20	Inhibition of Human Tumor-Infiltrating Lymphocyte Effector Functions by the Homophilic Carcinoembryonic Cell Adhesion Molecule 1 Interactions. <i>Journal of Immunology</i> , 2006, 177, 6062-6071.	0.8	52
21	Systemic dysregulation of CEACAM1 in melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 215-230.	4.2	48
22	Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. <i>Immunology</i> , 2009, 126, 186-200.	4.4	47
23	Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation. <i>Frontiers in Immunology</i> , 2017, 8, 1211.	4.8	47
24	CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1833-1847.	4.2	43
25	Adoptive Cell Therapy for Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 48-53.	2.0	43
26	Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. , 2020, 8, e000148.		42
27	Focus on Adoptive T Cell Transfer Trials in Melanoma. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-11.	3.3	34
28	CEACAM1 Promotes Melanoma Cell Growth through Sox-2. <i>Neoplasia</i> , 2014, 16, 451-460.	5.3	29
29	Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies. <i>Journal of the National Cancer Institute</i> , 2022, 114, 436-445.	6.3	29
30	SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. <i>Oncotarget</i> , 2016, 7, 30166-30177.	1.8	29
31	Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy. <i>Oncolmmunology</i> , 2019, 8, e1672494.	4.6	28
32	Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies. <i>PLoS ONE</i> , 2013, 8, e57922.	2.5	27
33	CAR T cells induce a complete response in refractory Burkitt Lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1583-1585.	2.4	25
34	Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	24
35	Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. <i>Current Research in Translational Medicine</i> , 2020, 68, 17-22.	1.8	24
36	Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. <i>Molecular Carcinogenesis</i> , 2020, 59, 736-744.	2.7	24

#	ARTICLE	IF	CITATIONS
37	Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. , 2021, 9, e001743.		23
38	Tumor-Infiltrating Lymphocytes. Cancer Journal (Sudbury, Mass ), 2015, 21, 465-469.	2.0	22
39	Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leukemia and Lymphoma, 2021, 62, 1692-1701.	1.3	22
40	Adoptive T-cell transfer in melanoma. Immunotherapy, 2013, 5, 79-90.	2.0	21
41	Predictors of tumor-infiltrating lymphocyte efficacy in melanoma. Immunotherapy, 2016, 8, 35-43.	2.0	21
42	Reduced CTL motility and activity in avascular tumor areas. Cancer Immunology, Immunotherapy, 2019, 68, 1287-1301.	4.2	21
43	Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Cytotherapy, 2009, 11, 206-217.	0.7	20
44	Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients. Transfusion and Apheresis Science, 2020, 59, 102769.	1.0	19
45	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transplantation, 2021, 56, 1134-1143.	2.4	17
46	Immunotherapy for the Management of Advanced Melanoma: The Next Steps. American Journal of Clinical Dermatology, 2013, 14, 261-272.	6.7	15
47	Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40. Journal of Immunology, 2018, 201, 2959-2968.	0.8	14
48	Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma. Transplantation and Cellular Therapy, 2022, 28, 251-257.	1.2	14
49	Remission of acute myeloid leukemia with t(8;21) following CD19 CAR T-cells. Leukemia, 2020, 34, 1939-1942.	7.2	12
50	Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies. Blood, 2019, 134, 3234-3234.	1.4	12
51	CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis. Oncotarget, 2016, 7, 17885-17895.	1.8	12
52	Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center. Israel Medical Association Journal, 2006, 8, 164-8.	0.1	12
53	Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Experimental and Therapeutic Medicine, 2012, 3, 898-902.	1.8	11
54	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biology, 2014, 4, 140030.	3.6	11

#	ARTICLE	IF	CITATIONS
55	Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells. <i>Neoplasia</i> , 2018, 20, 401-409.	5.3	11
56	Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma. <i>Oncotarget</i> , 2017, 8, 99580-99586.	1.8	10
57	Parameters of long-term response with CD28-based CD19 chimaeric antigen receptor-modified T cells in children and young adults with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 475-481.	2.5	10
58	CT halo sign as an imaging marker for response to adoptive cell therapy in metastatic melanoma with pulmonary metastases. <i>European Radiology</i> , 2014, 24, 1251-1256.	4.5	9
59	Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma. <i>Anticancer Research</i> , 2019, 39, 4995-5001.	1.1	9
60	Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. <i>Journal of Immunotherapy</i> , 2019, 42, 43-50.	2.4	9
61	Collection of Large-scale Expanded Lymphocyte Cultures for Adoptive Immunotherapy Using a COBE Spectra Apheresis Machine. <i>Journal of Immunotherapy</i> , 2008, 31, 563-568.	2.4	8
62	Ras Oncoproteins Transfer from Melanoma Cells to T Cells and Modulate Their Effector Functions. <i>Journal of Immunology</i> , 2012, 189, 4361-4370.	0.8	8
63	Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies. <i>Cells</i> , 2022, 11, 1140.	4.1	8
64	Is there a future for adoptive cell transfer in melanoma patients?. <i>OncolImmunology</i> , 2013, 2, e26098.	4.6	7
65	Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes. <i>Journal of Immunotherapy</i> , 2016, 39, 218-222.	2.4	7
66	First-in-Human Mitochondrial Augmentation of Hematopoietic Stem Cells in Pearson Syndrome. <i>Blood</i> , 2018, 132, 1024-1024.	1.4	7
67	Normal human CD4+ helper T cells express Kv1.1 voltage-gated K+ channels, and selective Kv1.1 block in T cells induces by itself robust TNF $\alpha$ production and secretion and activation of the NF $\kappa$ B non-canonical pathway. <i>Journal of Neural Transmission</i> , 2016, 123, 137-157.	2.8	6
68	microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1541-1555.	4.2	4
69	Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. <i>Cancer Immunology Research</i> , 2022, 10, 1127-1140.	3.4	4
70	Genetic Modification of Tumor-Infiltrating Lymphocytes via Retroviral Transduction. <i>Frontiers in Immunology</i> , 2020, 11, 584148.	4.8	2
71	Encouraging Survival and High Rates of Toxicity: Allogeneic Hematopoietic Cell Transplantation after Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Aggressive Lymphoma Patients. <i>Blood</i> , 2021, 138, 910-910.	1.4	1